专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180071384A1 VACCINES BASED ON HEPATITIS B CORE ANTIGENS 审中-公开
公开(公告)号：US20180071384A1
公开(公告)日：2018-03-15
申请号：US15560462
申请日：2016-03-24
申请人： IQUR LIMITED
发明人： Michael Anthony Whelan , Robert A. Field , David J. Rowlands
IPC分类号： A61K39/29 , A61K39/02 , A61K39/385 , C07K14/02 , C12N7/00
CPC分类号： A61K39/292 , A61K39/0208 , A61K39/385 , A61K2039/5256 , A61K2039/5258 , A61K2039/6075 , A61K2039/64 , A61K2039/70 , C07K14/005 , C07K14/02 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , C12N2730/10134 , C12N2730/10151 , C12N2730/10171
摘要： The invention provides a protein comprising hepatitis B core antigen (HBcAg) with a sequence of the formula XpZqXr in an e1 loop, wherein X is a negatively charged amino acid residue, Z is a positively charged amino acid residue, and p, q N and r are each independently an integer from 1 to 12, and wherein a sugar is attached to a Z residue. The protein may comprise a first and a second copy of HBcAg in tandem, wherein one or both copies of HBcAg has a sugar attached to the e1 loop. The first copy may have a sugar attached to the e1 loop and the second copy may comprise a peptide epitope in the e1 loop. The protein may be used to induce an immune response against the sugar and hence act as a vaccine.

2. 发明申请

US20170327797A1 RECOMBINANT HBV CCCDNA, THE METHOD TO GENERATE THEREOF AND THE USE THEREOF 审中-公开
公开(公告)号：US20170327797A1
公开(公告)日：2017-11-16
申请号：US15661283
申请日：2017-07-27
申请人： Hoffmann-La Roche Inc.
发明人： Lu Gao , Hui Hu , Zhipeng Yan , Kunlun Xiang , Youjun Yu , Jing Zeng
IPC分类号： C12N7/00 , C07K14/005 , G01N33/576 , C12Q1/70 , G01N33/50 , C12P19/34 , A01K67/027
CPC分类号： C12N7/00 , A01K67/027 , A01K2207/05 , A01K2227/105 , A01K2267/0337 , A61K49/0008 , C07K14/005 , C12N2730/10121 , C12N2730/10151 , C12N2800/30 , C12N2800/50 , C12N2800/80 , C12P19/34 , C12Q1/706 , C12Q2600/136 , G01N33/5088 , G01N33/5761 , G01N2333/02 , G01N2500/10
摘要： The present invention relates to a recombinant HBV cccDNA comprising HBV genome or the fragment or variant thereof and a site-hybrid insert, a method to generate said recombinant HBV cccDNA, a method for establishment of an in vitro or in vivo cccDNA based model for persistently hepatitis B virus replication by using the recombinant HBV cccDNA of the present invention, and a method for anti-HBV drug evaluation.

3. 发明申请

US20160122420A1 ANTIBODY DISPLAY 审中-公开
标题翻译：抗体显示
公开(公告)号：US20160122420A1
公开(公告)日：2016-05-05
申请号：US14896343
申请日：2014-06-05
申请人： David J. ROWLANDS , George LOMONOSSOFF , Hadrien PEYRET
发明人： David J. ROWLANDS , George LOMONOSSOFF , Hadrien PEYRET
IPC分类号： C07K16/18 , C12N7/00 , G01N33/68 , C07K14/005
CPC分类号： C07K16/18 , C07K14/005 , C07K14/02 , C07K16/00 , C07K2317/22 , C07K2317/569 , C07K2319/35 , C07K2319/735 , C07K2319/75 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , C12N2730/10134 , C12N2730/10142 , C12N2730/10151 , G01N33/6857 , G01N2333/02
摘要： The invention provides a protein comprising a first and a second copy of hepatitis B core antigen (HBcAg) in tandem, in which one or both of the copies of HBcAg comprises a single-domain antibody fragment in the el loop.
摘要翻译：本发明提供一种包含乙型肝炎核心抗原（HBcAg）的第一和第二拷贝的蛋白质，其中HBcAg的一个或两个拷贝在el环中包含单结构域抗体片段。

4. 发明授权

US08882484B2 Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells 有权
标题翻译：用于在表达HBX的哺乳动物细胞中产生重组蛋白的方法和组合物
公开(公告)号：US08882484B2
公开(公告)日：2014-11-11
申请号：US12995177
申请日：2009-05-27
申请人： Fang Jin , Richard N. Harkins , Maxine Bauzon , Terry Hermiston
发明人： Fang Jin , Richard N. Harkins , Maxine Bauzon , Terry Hermiston
IPC分类号： C12P1/00 , C12P21/06 , C12P21/04 , C12P21/02
CPC分类号： C07K14/005 , C12N7/00 , C12N2730/10151 , C12P21/02
摘要： The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consisting of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.
摘要翻译：本发明的方法通过生长选自HKB11，CHO，BHK21，C2C12和HEK293细胞的哺乳动物宿主细胞，提供了具有编码乙型肝炎病毒蛋白和异源蛋白质的核酸的哺乳动物宿主细胞中的异源蛋白质，通过在非粘附悬浮培养物中生长哺乳动物宿主细胞，或通过生长含有提供外源X盒结合蛋白XBP1的核酸的哺乳动物宿主细胞。条件应该是这样的，如果存在HBx，外源XBP1，并且异源蛋白质由哺乳动物细胞表达。本发明包括用于实施该方法的组合物。

5. 发明申请

US20140322704A1 Hepatitis Virus Culture Systems Using Stem Cell-Derived Human Hepatocyte-Like Cells and Their Methods of Use 审中-公开
标题翻译：使用干细胞衍生的人肝细胞样细胞的肝炎病毒培养系统及其使用方法
公开(公告)号：US20140322704A1
公开(公告)日：2014-10-30
申请号：US14366467
申请日：2012-12-19
申请人： The Florida State University Research Foundation, Inc.
发明人： Hengli Tang , Xianfang Wu
IPC分类号： C12N7/00 , C12Q1/02 , C12N5/071
CPC分类号： C12N7/00 , C12N5/067 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/12 , C12N2501/16 , C12N2501/385 , C12N2501/415 , C12N2503/02 , C12N2506/02 , C12N2506/45 , C12N2730/10151 , C12N2770/24251 , C12Q1/025 , C12Q1/18 , G01N33/5067 , G01N33/5767
摘要： The invention relates to the discovery that DHH derived from stem cells are permissive for infection by hepatitis viruses (HV), such as hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV) and hepatitis E virus (HEV). Included in the invention are HV-permissive DHHs and methods of making an HCV-permissive DHH derived from a stem cell. Also included is an HV culture system comprising at least one HV-permissive DHH. The HV-permissive DHH and HV culture system are useful for conducting HV life cycle analyses, diagnosing a subject as being infected with HV, genotyping and characterizing the HV of a subject infected with HV, detecting drug resistance of HV obtained from a subject infected with HV, screening for and identify modulators of HV infection, and monitoring the effect of a treatment of HV in a subject.
摘要翻译：本发明涉及从干细胞衍生的DHH允许肝炎病毒（HV）如甲型肝炎病毒（HAV），乙型肝炎病毒（HBV），丙型肝炎病毒（HCV），丙型肝炎病毒（HCV） HDV）和戊型肝炎病毒（HEV）。本发明中包括HV允许DHH和制备衍生自干细胞的HCV允许DHH的方法。还包括HV培养系统，其包括至少一种HV允许DHH。 HV允许DHH和HV培养系统可用于进行HV生命周期分析，诊断被感染HV的受试者，对感染HV的受试者的HV进行基因分型和表征，检测从感染的受试者获得的HV的耐药性 HV，筛选和鉴定HV感染的调节剂，并监测受试者中HV的治疗效果。

6. 发明申请

US20140315276A1 SYNTHESIS OF LINEAR AND BRANCHED POLYMERS OF POLYPEPTIDES THROUGH DIRECT CONJUGATION 有权
标题翻译：通过直接结合合成多肽的线性和分支聚合物
公开(公告)号：US20140315276A1
公开(公告)日：2014-10-23
申请号：US14196851
申请日：2014-03-04
申请人： The Board of Trustees of the Leland Stanford Junior University
发明人： Cem Albayrak , James R. Swartz , Yuan Lu
IPC分类号： C12N7/00 , C07K14/005 , C12P21/00
CPC分类号： C12N7/00 , C07K1/1075 , C07K14/005 , C12N2730/10122 , C12N2730/10123 , C12N2730/10151 , C12P21/02
摘要： Methods are provided for a one step synthesis of polypeptide polymers or co-polymers. The polymers or co-polymers can be linear or branched. In the methods of the invention, the coding sequence for the polypeptide(s) to be polymerized is altered by introducing one or more codons for an nonnatural amino acid, which coding sequence is then utilized to produce the cognate polypeptide. The nonnatural amino acids are selected to be reactive with each other in a bioorthogonal reaction, and are combined in a conjugation reaction with the desired components of the polymer.
摘要翻译：提供了一步合成多肽聚合物或共聚物的方法。聚合物或共聚物可以是直链或支链的。在本发明的方法中，通过为非天然氨基酸引入一个或多个密码子来改变要聚合的多肽的编码序列，然后将该编码序列用于产生同源多肽。选择非天然氨基酸在生物正交反应中彼此反应，并将其与共聚反应与聚合物的所需组分结合。

7. 发明申请

US20090048433A1 Scalable Process for Protein Purification 有权
标题翻译：蛋白质纯化的可扩展过程
公开(公告)号：US20090048433A1
公开(公告)日：2009-02-19
申请号：US11922591
申请日：2006-06-20
申请人： Susanne Richter , Simon Topell
发明人： Susanne Richter , Simon Topell
IPC分类号： C07K1/00
CPC分类号： C07K14/005 , C07K1/165 , C07K1/22 , C12N7/00 , C12N2730/10123 , C12N2730/10151 , C12N2795/18123 , C12N2795/18151
摘要： The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.
摘要翻译：本发明提供了从细菌宿主的匀浆中纯化重组表达的自组装VLP的方法，其中该方法可以以成本有效的方式扩大到商业生产规模。该方法包括使用阴离子交换基质的第一层析，使用羟基磷灰石的第二层析和任选的尺寸排阻层析。通过本发明方法获得的VLP制剂基本上不含内毒素污染物。

8. 发明申请

US20150315246A1 SCALABLE PROCESS FOR PROTEIN PURIFICATION 有权
标题翻译：蛋白质纯化的可扩展过程
公开(公告)号：US20150315246A1
公开(公告)日：2015-11-05
申请号：US14596978
申请日：2015-01-14
申请人： Cytos Biotechnology AG
发明人： SUSANNE RICHTER , Simon Topell
IPC分类号： C07K14/005 , C07K1/16 , C07K1/22
CPC分类号： C07K14/005 , C07K1/165 , C07K1/22 , C12N7/00 , C12N2730/10123 , C12N2730/10151 , C12N2795/18123 , C12N2795/18151
摘要： The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.
摘要翻译：本发明提供了从细菌宿主的匀浆中纯化重组表达的自组装VLP的方法，其中该方法可以以成本有效的方式扩大到商业生产规模。该方法包括使用阴离子交换基质的第一层析，使用羟基磷灰石的第二层析和任选的尺寸排阻层析。通过本发明方法获得的VLP制剂基本上不含内毒素污染物。

9. 发明授权

US08124409B2 Utilizing liver cell line QSG-7701 to be infected with hepatitis B virus 失效
标题翻译：利用肝细胞系QSG-7701感染乙型肝炎病毒
公开(公告)号：US08124409B2
公开(公告)日：2012-02-28
申请号：US12523085
申请日：2008-01-29
申请人： Xiaoben Pan , Lai Wei
发明人： Xiaoben Pan , Lai Wei
IPC分类号： C12N5/10 , C07N7/06
CPC分类号： C12N7/00 , C12N2730/10151
摘要： The use of the liver cell line QSG-7701 for HBV infection includes the following steps: directly infecting QSG-7701 cells with purified HBV particles and facilitating the infection by DMSO and/or PEG treatment. The easily available QSG-7701 liver cell line may not require pre-differentiation induction and is naturally susceptible for HBV infection. This cell line provides near normal physiological conditions for HBV infection, especially the infection conditions that are characterized with Chinese origin. This cell line is suitable for investigating the life cycle of HBV. Therefore, this cell line is useful for the investigation of viral infection processes and for the development of drugs that specifically target these processes.
摘要翻译：肝细胞系QSG-7701用于HBV感染的方法包括以下步骤：用纯化的HBV颗粒直接感染QSG-7701细胞，并促进通过DMSO和/或PEG处理的感染。容易获得的QSG-7701肝细胞系可能不需要预分化诱导，并且对HBV感染天然易感。该细胞系为HBV感染提供接近正常的生理条件，特别是以中国血清为特征的感染病症。该细胞系适用于调查HBV的生命周期。因此，这种细胞系可用于病毒感染过程的研究和用于开发专门针对这些过程的药物。

10. 发明申请

US20110306113A1 Scalable Process for Protein Purification 审中-公开
标题翻译：蛋白质纯化的可扩展过程
公开(公告)号：US20110306113A1
公开(公告)日：2011-12-15
申请号：US12978333
申请日：2010-12-23
申请人： Susanne RICHTER , Simon Topell
发明人： Susanne RICHTER , Simon Topell
IPC分类号： C12N7/02
CPC分类号： C07K14/005 , C07K1/165 , C07K1/22 , C12N7/00 , C12N2730/10123 , C12N2730/10151 , C12N2795/18123 , C12N2795/18151
摘要： The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.
摘要翻译：本发明提供了从细菌宿主的匀浆中纯化重组表达的自组装VLP的方法，其中该方法可以以成本有效的方式扩大到商业生产规模。该方法包括使用阴离子交换基质的第一层析，使用羟基磷灰石的第二层析和任选的尺寸排阻层析。通过本发明方法获得的VLP制剂基本上不含内毒素污染物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式